The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease

Journal of the American College of Cardiology

Volumn 58, Issue 20, 2011, Pages 2068-2075

  Patel, Parin J ^a,b   Khera, Amit V ^b,c,d   Jafri, Kashif ^b   Wilensky, Robert L ^a,c   Rader, Daniel J ^a,b,c,d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Cardiovascular Institute   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

acute coronary syndrome(s); coronary artery disease; HDL function; HDL inflammatory index; oxidized LDL

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ANGIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STABLE CORONARY ARTERY DISEASE; SYMPTOMATOLOGY; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE CORONARY SYNDROME; AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 80155198250     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.08.030     Document Type: Article

References (46)

1. D.J. Gordon, J.L. Probstfield, and R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease Four prospective American studies Circulation 79 1989 8 15 (Pubitemid 19043669)
2. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, and W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847 (Pubitemid 28213628)
3. V.J. Carey, L. Bishop, N. Laranjo, B.J. Harshfield, C. Kwiat, and F.M. Sacks Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control Am J Cardiol 106 2010 757 763
4. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122 (Pubitemid 350146106)
5. B. Agerholm-Larsen, B.G. Nordestgaard, R. Steffensen, G. Jensen, and A. Tybjaerg-Hansen Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene Circulation 101 2000 1907 1912 (Pubitemid 30225270)
6. J.D. Curb, R.D. Abbott, and B.L. Rodriguez A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly J Lipid Res 45 2004 948 953 (Pubitemid 38552866)
7. C.R. Sirtori, L. Calabresi, and G. Franceschini Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study Circulation 103 2001 1949 1954 (Pubitemid 32322221)
8. E.M. deGoma, R.L. deGoma, and D.J. Rader Beyond high-density lipoprotein cholesterol levelsevaluating high-density lipoprotein function as influenced by novel therapeutic approaches J Am Coll Cardiol 51 2008 2199 2211 (Pubitemid 351754991)
9. D.J. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 2006 3090 3100 (Pubitemid 44878620)
10. D. Sviridov, N. Mukhamedova, A.T. Remaley, J. Chin-Dusting, and P. Nestel Antiatherogenic functionality of high density lipoprotein: how much versus how good J Atheroscler Thromb 15 2008 52 62
11. A.V. Khera, M. Cuchel, and M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
12. M. Navab, S.Y. Hama, G.P. Hough, G. Subbanagounder, S.T. Reddy, and A.M. Fogelman A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids J Lipid Res 42 2001 1308 1317 (Pubitemid 32744255)
13. B.J. Ansell, M. Navab, and S. Hama Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756 (Pubitemid 37498976)
14. C. Charles-Schoeman, J. Watanabe, and Y.Y. Lee Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis Arthritis Rheum 60 2009 2870 2879
15. S. Dodani, R. Kaur, S. Reddy, G.L. Reed, M. Navab, and V. George Can dysfunctional HDL explain high coronary artery disease risk in South Asians? Int J Cardiol 129 2008 125 132
16. K. Kalantar-Zadeh, J.D. Kopple, N. Kamranpour, A.M. Fogelman, and M. Navab HDL-inflammatory index correlates with poor outcome in hemodialysis patients Kidney Int 72 2007 1149 1156 (Pubitemid 47609043)
17. M. Navab, P. Ruchala, and A.J. Waring A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids J Lipid Res 50 2009 1538 1547
18. N.D. Vaziri, H. Moradi, M.V. Pahl, A.M. Fogelman, and M. Navab In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide Kidney Int 76 2009 437 444
19. L. Wang, W.-Z. Chen, and M.P. Wu Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the plasma HDL inflammatory index Cytokine 49 2010 194 200
20. C.E. Watson, N. Weissbach, and L. Kjems Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function J Lipid Res 52 2010 361 373
21. M. Lehrke, S.C. Millington, and M. Lefterova CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans J Am Coll Cardiol 49 2007 442 449 (Pubitemid 46135882)
22. M. Dobiásová, J. Frohlich, M. Sedová, M.C. Cheung, and B.G. Brown Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography J Lipid Res 52 2011 566 571
23. N. Shuhei, S. Söderlund, M. Jauhiainen, and M.R. Taskinen Effect of HDL composition and particle size on the resistance of HDL to the oxidation Lipids Health Dis 9 2010 104
24. A. Helgadottir, A. Manolescu, and A. Helgason A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction Nat Genet 38 2006 68 74 (Pubitemid 43011884)
25. S. Kathiresan, B.F. Voight, S. Purcell Myocardial Infarction Genetics Consortium Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants Nat Genet 41 2009 334 341
26. B. Ky, A. Burke, and S. Tsimikas The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans J Am C Cardiol 51 2008 1653 1662 (Pubitemid 351626406)
27. R.A. Guy, G.F. Maguire, I. Crandall, P.W. Connelly, and K.C. Kain Characterization of peroxynitrite-oxidized low density lipoprotein binding to human CD36 Atherosclerosis 155 2001 19 28 (Pubitemid 32167120)
28. J. Frohlich, and M. Dobiásová Fractional esterification rate of cholesterol and ratio of triglycerides to hdl-cholesterol are powerful predictors of positive findings on coronary angiography Clin Chem 49 2003 1873 1880 (Pubitemid 37340322)
29. Z. Julia, E. Duchene, and N. Fournier Postprandial lipemia enhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia J Lipid Res 51 2010 3350 3358
30. M. McMahon, J. Grossman, and J. FitzGerald Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis Arthritis Rheum 54 2006 2541 2549 (Pubitemid 44205015)
31. C. Di Filippo, S. Cuzzocrea, F. Rossi, R. Marfella, and M. D'Amico Oxidative stress as the leading cause of acute myocardial infarction in diabetics Cardiovasc Drug Rev 24 2006 77 87 (Pubitemid 46696918)
32. L. Lorgis, M. Zeller, and G. Dentan The free oxygen radicals test (FORT) to assess circulating oxidative stress in patients with acute myocardial infarction Atherosclerosis 213 2010 616 621
33. M. Dobiasova, and J. Frohlich The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)) Clin Biochem 34 2001 583 588 (Pubitemid 34014853)
34. M. Dobiasova, J. Stribrna, D.L. Sparks, P.H. Pritchard, and J.J. Frohlich Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease Arterioscler Thromb 11 1991 64 70
35. M.H. Tan, D. Johns, and N.B. Glazer Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes Clin Chem 50 2004 1184 1188 (Pubitemid 38824226)
36. M.H. Tan, K.C. Loh, M. Dobiasova, and J.J. Frohlich Fractional esterification rate of HDL particles in patients with type 2 diabetes Relation to coronary heart disease risk factors Diabetes Care 21 1998 139 142 (Pubitemid 28030401)
37. L.C.L. Correia, M.S. Rocha, and J.P. Esteves HDL-cholesterol level provides additional prognosis in acute coronary syndromes Int J Cardiol 136 2009 307 314
38. A. Sachdeva, C.P. Cannon, and P.C. Deedwania Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines Am Heart J 157 2009 1117.e2
39. R. Wolfram, H.B. Brewer, and Z. Xue Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with nonST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation Am J Cardiol 98 2006 711 717 (Pubitemid 44300998)
40. M. Gomaraschi, L. Calabresi, and G. Rossoni Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides J Pharmacol Exp Therapeut 324 2007 776 783
41. R.J. Bisoendial, G.K. Hovingh, and J.H. Levels Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein Circulation 107 2003 2944 2948 (Pubitemid 36736637)
42. L.E. Spieker, I. Sudano, and D. Hrlimann High-density lipoprotein restores endothelial function in hypercholesterolemic Men Circulation 105 2002 1399 1402 (Pubitemid 34263266)
43. K. Tan, W.S. Chow, and J.C. Lam HDL dysfunction in obstructive sleep apnea Atherosclerosis 184 2006 377 382 (Pubitemid 43049723)
44. J. Desouza, C. Vindis, and B. Hansel Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity Atherosclerosis 197 2008 84 94 (Pubitemid 351273276)
45. B. Hansel, P. Giral, and E. Nobecourt Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity J Clin Endocrinol Metab 89 2004 4963 4971 (Pubitemid 39391435)
46. P.S. Green, T. Vaisar, and S. Pennathur Combined statin and niacin therapy remodels the high-density lipoprotein proteome Circulation 118 2008 1259 1267